https://doi.org/10.4081/monaldi.2022.2281

Tuberculosis endemicity and BCG vaccination: Protection against COVID-19

By Y tambe - Y tambe's file, CC BY-SA 3.0, https://commons.wikimedia.org/w/index.php?curid=1827666
Vol. 93 No. 1 (2023)
Submitted: March 30, 2022
Accepted: June 13, 2022
Published: June 24, 2022
tuberculosis, COVID-19, BCG
Abstract Views: 907
PDF: 243
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

Tarun Krishna Boppana
https://orcid.org/0000-0002-9970-3712
Department of Pulmonary, Critical care and Sleep Medicine, All India Institute of Medical Sciences (AIIMS), New Delhi, India.
Saurabh Mittal
saurabh_kgmu@yahoo.co.in
https://orcid.org/0000-0002-7979-6405
Department of Pulmonary, Critical care and Sleep Medicine, All India Institute of Medical Sciences (AIIMS), New Delhi, India.
Karan Madan
Department of Pulmonary, Critical care and Sleep Medicine, All India Institute of Medical Sciences (AIIMS), New Delhi, India.
Anant Mohan
Department of Pulmonary, Critical care and Sleep Medicine, All India Institute of Medical Sciences (AIIMS), New Delhi, India.
Vijay Hadda
https://orcid.org/0000-0001-5820-3685
Department of Pulmonary, Critical care and Sleep Medicine, All India Institute of Medical Sciences (AIIMS), New Delhi, India.
Randeep Guleria
https://orcid.org/0000-0002-6258-2160
Department of Pulmonary, Critical care and Sleep Medicine, All India Institute of Medical Sciences (AIIMS), New Delhi, India.

The coronavirus disease 2019 (COVID-19) has affected different countries in a differential manner. The host susceptibility and host factors are important parameters for this variability. This study aimed to assess the effect of tuberculosis (TB) endemicity and Bacille Calmette-Guerin (BCG) coverage on COVID-19. Available data regarding TB incidence, BCG coverage (as per the World Health Organization), and COVID-19 incidence of 168 countries as of 19th September 2021was collected. Countries were divided into four cohorts based upon annual TB incidence and BCG coverage and COVID-19 incidence and case fatality rates were compared using the Kruskal-Wallis test. Countries with low TB incidence and low BCG coverage had the highest COVID-19 incidence per lac population. However, no significant difference was seen in COVID-19 cases fatality rate. Higher TB incidence and BCG coverage were associated with lesser incidence of COVID-19. This result paves the way for research into pathogenesis and host immune response in COVID-19.

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.

Citations

Crossref
Scopus
Google Scholar
Europe PMC
Pahuja S, Madan M, Mittal S, et al. Weather parameters and COVID-19: A Correlational analysis. J Occup Environ Med 2021;63:69–73. DOI: https://doi.org/10.1097/JOM.0000000000002082
Madan M, Pahuja S, Mohan A, et al. TB infection and BCG vaccination: are we protected from COVID-19? Public Health 2020;185:91–2. DOI: https://doi.org/10.1016/j.puhe.2020.05.042
Miller A, Reandelar MJ, Fasciglione K, et al. Correlation between universal BCG vaccination policy and reduced morbidity and mortality for COVID-19: an epidemiological study. medRxiv 2020.03.24.20042937. DOI: https://doi.org/10.1101/2020.03.24.20042937
World Health Organization. Coronavirus disease (COVID-19). Accessed: 2021 Oct 22. Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019
World Health Organization. Global Tuberculosis Report. Accessed: 2021 Oct 22. Available from: https://www.who.int/teams/global-tuberculosis-programme/tb-reports
Worldometer [Internet]. Coronavirus Cases (Live). Accessed: 5 September 2020. Available from: https://www.worldometers.info/coronavirus/
Lyadova IV, Panteleev AV. Th1 and Th17 cells in tuberculosis: Protection, pathology, and biomarkers. Mediators Inflamm 2015;2015:1–13. DOI: https://doi.org/10.1155/2015/854507
Boppana TK, Mohan A, Madan K, et al. Candidate immunomodulators for COVID-19: Heat-killed Mycobacterium w and BCG vaccine. Adv Respir Med 2021;89:350-1. DOI: https://doi.org/10.5603/ARM.a2021.0043
Prompetchara E, Ketloy C, Palaga T. Immune responses in COVID-19 and potential vaccines: Lessons learned from SARS and MERS epidemic. Asian Pac J Allergy Immunol 2020;38:1–9.
Giamarellos-Bourboulis EJ, Tsilika M, Moorlag S, et al. Activate: Randomized clinical trial of BCG vaccination against infection in the elderly. Cell 2020;183:315-323.e9. DOI: https://doi.org/10.1016/j.cell.2020.08.051
Clinicaltrials.gov [Internet]. Identifier: NCT04475302, BCG vaccine in reducing morbidity and mortality in elderly individuals in COVID-19 hotspots in India; 2020 Jul 17 [cited 2022 May 16]. Available from: https://clinicaltrials.gov/ct2/show/NCT04475302
Madan M, Baldwa B, Raja A, et al. Impact of latent tuberculosis on severity and outcomes in admitted COVID-19 patients. Cureus 2021;13:e19882. DOI: https://doi.org/10.7759/cureus.19882

How to Cite

Boppana, Tarun Krishna, Saurabh Mittal, Karan Madan, Anant Mohan, Vijay Hadda, and Randeep Guleria. 2022. “Tuberculosis Endemicity and BCG Vaccination: Protection Against COVID-19”. Monaldi Archives for Chest Disease 93 (1). https://doi.org/10.4081/monaldi.2022.2281.
Copyright (c) 2022 The Author(s) Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.


Similar Articles

<< < 4 5 6 7 8 9 10 11 12 13 > >> 

You may also start an advanced similarity search for this article.